Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Cantor Fitzgerald
Boehringer Ingelheim
Novartis
Deloitte
McKesson
Moodys
US Department of Justice
Mallinckrodt
Julphar

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,993,600

« Back to Dashboard

Which drugs does patent 8,993,600 protect, and when does it expire?

Patent 8,993,600 protects ORKAMBI and is included in one NDA.

This patent has forty-eight patent family members in twenty-three countries.
Summary for Patent: 8,993,600
Title:Modulators of ATP-binding cassette transporters
Abstract: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
Inventor(s): Hadida Ruah; Sara S. (La Jolla, CA), Hamilton; Matthew (Hackettstown, NJ), Miller; Mark (San Diego, CA), Grootenhuis; Peter D. J. (San Diego, CA), Bear; Brian (Oceanside, CA), McCartney; Jason (Cardiff by the Sea, CA), Zhou; Jinglan (San Diego, CA)
Assignee: Vertex Pharmaceuticals Incorporated (Boston, MA)
Application Number:12/114,935
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,993,600

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Vertex Pharms Inc ORKAMBI ivacaftor; lumacaftor TABLET;ORAL 206038-002 Sep 28, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Vertex Pharms Inc ORKAMBI ivacaftor; lumacaftor TABLET;ORAL 206038-001 Jul 2, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,993,600

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,973,038 Modulators of ATP-binding cassette transporters ➤ Subscribe
9,216,969 Modulators of ATP-binding cassette transporters ➤ Subscribe
7,659,268 Modulators of ATP-binding cassette transporters ➤ Subscribe
8,324,207 Modulators of ATP-binding cassette transporters ➤ Subscribe
7,741,321 Modulators of ATP-binding cassette transporters ➤ Subscribe
8,012,999 Modulators of CFTR ➤ Subscribe
7,956,052 Modulators of ATP-binding cassette transporters ➤ Subscribe
7,754,739 Modulators of CFTR ➤ Subscribe
8,741,933 Modulators of ATP-binding cassette transporters ➤ Subscribe
8,318,733 Modulators of ATP-binding cassette transporters ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,993,600

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 2774925 ➤ Subscribe
Slovenia 2404919 ➤ Subscribe
Slovenia 2395002 ➤ Subscribe
Slovenia 1945632 ➤ Subscribe
Russian Federation 2608610 ➤ Subscribe
Russian Federation 2012123372 ➤ Subscribe
Russian Federation 2463303 ➤ Subscribe
Russian Federation 2008122929 ➤ Subscribe
Portugal 2774925 ➤ Subscribe
Portugal 2404919 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Novartis
Argus Health
Farmers Insurance
Medtronic
Queensland Health
Covington
US Army
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot